What is the translation of " SINGLE-DOSE STUDY " in Croatian?

• ispitivanju jednokratne doze

Examples of using Single-dose study in English and their translations into Croatian

A single-dose study in subjects with varying degrees of liver cirrhosis Child-Pugh Classes A, B, and.
Ispitivanje jednokratne doze u ispitanika s različitim stupnjevima ciroze jetre Child-Pugh stadij A, B.

The pharmacokinetics of desloratadine in patients with chronic renal insufficiency(CRI) was compared with that of healthy subjects in one single-dose study and one multiple dose study..
Bolesnici s oštećenjem funkcije bubrega Farmakokinetika desloratadina u bolesnika s kroničnom insuficijencijom bubrega bila je uspoređivana s onom u zdravih ispitanika u jednom ispitivanju jednokratnih doza te u ispitivanju višekratnih doza.

However, in an in vivo single-dose study in conscious telemetered monkeys, there were no changes in QT interval or ECG wave form.
Međutim, u telemetrijskom ispitivanju in vivo pojedinačne doze u budnih majmuna nije bilo promjena u QT intervalu ili obliku EKG valova.

In a single-dose study, there were no clinically significant effects on retigabine AUC in volunteers with mild hepatic impairment Child-Pugh score 5 to 6.
U ispitivanju jednokratne doze na dobrovoljcima s blagim oštećenjem jetre(Child-Pugh zbroj bodova 5 do 6) nisu uočene klinički značajne promjene AUC-a retigabina.

In a single-dose study in healthy subjects, the administration of famotidine 10 hours prior to a single dose of SPRYCEL reduced dasatinib exposure by 61.
U ispitivanju pojedinačne doze u zdravih ispitanika, primjenom famotidina 10 sati prije pojedinačne doze lijeka SPRYCEL smanjila se izloženost dasatinibu za 61.

In an open single-dose study in adult patients with Sickle Cell Syndrome(Yan JH et al, 2005) the influence of renal function on pharmacokinetics of hydroxycarbamide was assessed.
U otvorenoj studiji jednokratnog doziranja kod odraslih bolesnika sa sindromom srpastih stanica(Yan JH et al, 2005) ocijenjivao se utjecaj renalne funkcije na farmakokinetiku hidroksikarbamida.

In a single-dose study, the pharmacokinetics of silodosin was not altered in nine patients with moderate hepatic impairment(Child-Pugh scores 7 to 9), compared to nine healthy subjects.
U ispitivanju jednokratne doze, farmakokinetika silodozina nije bila izmijenjena u devet bolesnika s umjerenim oštećenjem funkcije jetre(Child-Pugh bodovi 7 do 9) u usporedbi s devet zdravih ispitanika.

A single-dose study of SIRTURO in 8 subjects with moderate hepatic impairment(Child-Pugh B) demonstrated exposure to bedaquiline and M2(AUC672h) was 19% lower compared to healthy subjects.
Ispitivanje primjene jedne doze lijeka SIRTURO u 8 ispitanika s umjerenim oštećenjem jetre(Child-Pugh B) pokazalo je izloženost bedakilinu i M2(AUC672h) bila je 19% niža u usporedbi sa zdravim ispitanicima.

In a single-dose study, half life was doubled in the single patient with severe hepatic impairment(Child Pugh Class C), indicating a potential for a much greater degree of accumulation.
U ispitivanju s primjenom jednokratne doze lijeka u jedinog bolesnika s teškim oštećenjem jetre(Child- Pugh stadij C) poluvijek efavirenza bio je dvostruko dulji, što upućuje na mogućnost puno veće akumulacije lijeka.

In a single-dose study of efavirenz, half-life was doubled in the single patient with severe hepatic impairment(Child-Pugh-Turcotte Class C), indicating a potential for a much greater degree of accumulation.
U ispitivanju efavirenza s jednokratkom dozom, poluvrijeme je udvostručeno u jedinog pacijenta s teškim oštećenjem funkcije jetre(stadij C Child-Pugh-Turcotte), što ukazuje na potencijal puno višeg stupnja akumulacije.

In the single-dose study, the exposure to desloratadine was approximately 2 and 2.5-fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects.
U ispitivanju jednokratnih doza, izloženost desloratadinu bila je približno 2 puta viša u ispitanika s blagom do umjerenom kroničnom insuficijencijom bubrega, i 2, 5 puta viša u ispitanika s teškom kroničnom insuficijencijom bubrega, nego u zdravih ispitanika.

In a single-dose study in patients with type 2 diabetes, treatment with 300 mg before a mixed meal delayed intestinal glucose absorption and reduced postprandial glucose through both a renal and a non-renal mechanism.
U ispitivanju jedne doze u bolesnika s dijabetesom tipa 2, liječenje s 300 mg prije mješovitog obroka odgodilo je apsorpciju glukoze u crijevima, te je smanjilo postprandijalnu glukozu i kroz bubrežni i kroz ne-bubrežni mehanizam.

In a single-dose study in healthy volunteers and subjects with end stage renal disease, the retigabine AUC was increased by approximately 100% in the subjects with end stage renal disease relative to healthy volunteers.
U ispitivanju jednokratne doze na zdravim dobrovoljcima i ispitanicima u završnom stadiju bolesti bubrega, AUC retigabina bio je povišen za gotovo 100% u ispitanika u završnom stadiju bolesti bubrega u odnosu na zdrave dobrovoljce.

In a single-dose study in rats, a semi-synthetic insulin human in a formulation with 400 IU/ml and excipients identical to the Insuman Implantable 400 IU/ml formulation was administered by intraperitoneal injection.
U ispitivanju jednokratne doze u štakora intraperitonejskom je injekcijom primijenjen polusintetski humani inzulin u formulaciji jačine 400 IU/ml i s pomoćnim tvarima identičnima onima u formulaciji lijeka Insuman Implantable 400 IU/ml.

In a single-dose study, exposure to silodosin(unbound) in subjects with mild(n=8) and moderate renal impairment(n=8) resulted, on average, in an increase of Cmax(1.6-fold) and AUC(1.7-fold) relative to subjects with normal renal function n=8.
U ispitivanju jednokratne doze, izloženost silodozinu(nevezanom) u ispitanika s blagim(n=8) i umjerenim oštećenjem funkcije bubrega(n=8) u prosjeku je rezultiralo povećanjem Cmax(1, 6 puta) i AUC(1, 7 puta) u usporedbi s onima u ispitanika s normalnom funkcijom bubrega n=8.

In a single-dose study, retigabine was eliminated more slowly by healthy elderly volunteers(66 to 82 years of age) relative to healthy young adult volunteers, resulting in a higher AUC(approximately 40 to 50%) and longer terminal half-life(30%) see section 4.2.
U ispitivanju jednokratne doze retigabin se u starijih zdravih dobrovoljaca(od 66 do 82 godine), u usporedbi sa zdravim mlađim dobrovoljcima, izlučivao sporije što je rezultiralo višim AUC-om(oko 40 do 50%) i dužim terminalnim poluvijekom(30%) vidjeti dio 4.2.

In a single-dose study(800 mg) in 12 patients and a multiple-dose study(800 mg) in 13 patients with mild to severe hepatic insufficiency(Child Pugh Class A, B and C), the Cmax, AUC and t1/2 of telithromycin were similar compared to those obtained in age- and sex-matched healthy subjects.
U ispitivanju s primjenom jedne doze(800 mg) u 12 bolesnika i u ispitivanju s primjenom višekratnih doza(800 mg) u 13 bolesnika s blagim do teškim oštećenjem jetre(Child Pugh stadij A, B i C), Cmax, AUC i t1/2 telitromicina bili su slični onima u zdravih osoba iste dobi i spola.

In a single-dose study, retigabine AUC was increased by approximately 30% in volunteers with mild renal impairment(creatinine clearance 50 to 80 ml/min) and by approximately 100% in volunteers with moderate to severe renal impairment(creatinine clearance< 50 ml/min), relative to healthy volunteers.
U ispitivanju jednokratne doze, AUC retigabina je bio povišen za oko 30% u dobrovoljaca s blagim oštećenjem bubrega(klirens kreatinina 50 do 80 ml/min), te za oko 100% u dobrovoljaca s umjerenim do teškim oštećenjem bubrega(klirens kreatinina< 50 ml/min) u usporedbi sa zdravim dobrovoljcima.

In a second single-dose study in subjects with end stage renal disease receiving chronic haemodialysis(n= 8), initiation of dialysis at approximately 4 hours after a single dose of retigabine(100 mg) resulted in a median reduction in retigabine plasma concentrations of 52% from the start to end of dialysis.
U drugom ispitivanju jednokratne doze u ispitanika u završnom stadiju bolesti bubrega na kroničnoj hemodijalizi(n=8), početak dijalize oko 4 sata nakon primjene jedne doze retigabina(100 mg), rezultirao je medijanom smanjenja plazmatske koncentracije retigabina od 52%, od početka pa do kraja dijalize.

A single-dose study in subjects with varying degrees of liver cirrhosis(Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro- aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.
Ispitivanje jednokratne doze u ispitanika s različitim stupnjevima ciroze jetre( Child-Pugh stadij A, B, i C) nije pokazalo da postoji značajan učinak oštećenja funkcije jetre na farmakokinetiku aripiprazola i dehidro-aripiprazola, ali ispitivanje je uključilo samo 3 bolesnika s cirozom jetre u stadiju C, što nije dovoljno da bi se mogli izvući zaključci o njihovom metaboličkom kapacitetu.

In single-dose studies in healthy volunteers, no interactions were observed between entacapone and imipramine or between entacapone and moclobemide.
U ispitivanjima s jednokratnom dozom na zdravim dobrovoljcima nisu opažene interakcije između entakapona i imipramina ili između entakapona i moklobemida.

There is no specific experience in the management of lenalidomide overdose in multiple myeloma patients, although in dose-ranging studies some patients were exposed to up to 150 mg, and in single-dose studies, some patients were exposed to up to 400 mg.
Ne postoji specifično iskustvo u zbrinjavanju predoziranja lenalidomidom u bolesnika s multiplim mijelomom, iako su u ispitivanjima raspona doza neki bolesnici bili izloženi dozama do 150 mg, a u ispitivanjima pojedinačne doze neki bolesnici bili su izloženi dozama do 400 mg.

A single-dose toxicology study was conducted in African green monkeys exposed to ocular irrigation solutions containing the combination of phenylehphrine and ketorolac used during lens replacement surgery.
Ispitivanje toksičnosti jedne doze provedeno je u afričkih zelenih majmuna izloženih otopinama za okularno ispiranje koje su sadržavale kombinaciju fenilefrina i ketorolaka korištenih tijekom kirurškog zahvata zamjene leće.

Based on the findings from a single-dose pharmacokinetic study, patients with mild, moderate or severe hepatic impairment may receive the recommended starting dose see sections 4.2 and 5.2.
Prema podacima iz farmakokinetičkih ispitivanja jednokratne doze bolesnici s blagim, umjerenim ili teškim oštećenjem jetre mogu primiti preporučenu početnu dozu vidjeti dio 4.2 i 5.2.

In a single-dose pharmacokinetic study of immediate-release exenatide in 13 patients with type 2 diabetes and between the ages of 12 and 16 years, administration of exenatide(5 mcg) resulted in slightly lower mean AUC(16% lower) and Cmax(25% lower) compared to those observed in adults.
U farmakokinetičkom ispitivanju s primjenom jedne doze eksenatida s trenutnim oslobađanjem u 13 bolesnika sa šećernom bolešću tipa 2 u dobi između 12 i 16 godina, primjena eksenatida(5 µg) rezultirala je nešto nižom srednjom vrijednošću AUC-a(16% niže) i Cmax(25% niže) u usporedbi s vrijednostima opaženih u odraslih.